Cenestin

Cenestin is a brand name of conjugated estrogens, approved by the FDA in the following formulation(s):

CENESTIN (estrogens, conjugated synthetic a - tablet; oral)

• 
  Manufacturer: TEVA WOMENS
  
  Approval date: March 24, 1999
  
  Strength(s): 0.625MG, 0.9MG
  


• 
  Manufacturer: TEVA WOMENS
  
  Approval date: March 13, 2000
  
  Strength(s): 1.25MG ^[RLD]


• 
  Manufacturer: TEVA WOMENS
  
  Approval date: June 21, 2002
  
  Strength(s): 0.3MG
  


• 
  Manufacturer: TEVA WOMENS
  
  Approval date: February 5, 2004
  
  Strength(s): 0.45MG
  

Has a generic version of Cenestin been approved?

No. There is currently no therapeutically equivalent version of Cenestin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cenestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical compositions of conjugated estrogens and methods for their use
  Patent 5,908,638
  Issued: June 1, 1999
  Inventor(s): Huber; Harold Eugene & Ryan; Mary Katherine
  Assignee(s): Duramed Pharmaceuticals, Inc.
  This invention relates to novel pharmaceutical compositions and methods for their preparation containing conjugated estrogens for the treatment of peri-menopausal, menopausal and post-menopausal disorders in women. The novel pharmaceutical compositions comprise a carrier base material and conjugated estrogens formed into a solid unit dosage form possessing a regular incremental release of the medicament upon oral administration. Further, the invention comprises the combination of conjugated estrogens with progestogens in a solid, shaped dosage unit. Specifically, the invention comprises the use of an organic excipient such as high molecular weight hydroxyalkyl alkylcelluloses. The use of an organic excipient such as hydroxypropylmethylcellulose in a stable, solid dosage formulation containing either conjugated estrogens alone or in combination with a progestogen is described.
  
  Patent expiration dates:
  
  
  • July 26, 2015
    
    ✓ 
    Drug product
  
  
  
  • July 26, 2015
    
  
  

See also...

• Cenestin Consumer Information (Wolters Kluwer)
• Cenestin Consumer Information (Cerner Multum)
• Conjugated Estrogens Consumer Information (Wolters Kluwer)
• Conjugated Estrogens (Synthetic A) Consumer Information (Wolters Kluwer)
• Conjugated Estrogens (Synthetic B) Consumer Information (Wolters Kluwer)
• Conjugated Estrogens Tablets Consumer Information (Wolters Kluwer)
• Conjugated estrogens Consumer Information (Cerner Multum)